Your browser doesn't support javascript.
loading
Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
Alton, E W F W; Boyd, A C; Cheng, S H; Davies, J C; Davies, L A; Dayan, A; Gill, D R; Griesenbach, U; Higgins, T; Hyde, S C; Innes, J A; McLachlan, G; Porteous, D; Pringle, I; Scheule, R K; Sumner-Jones, S.
Affiliation
  • Alton EW; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Department of Gene Therapy, Imperial College, London, UK.
  • Boyd AC; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Medical Genetics Section, Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • Cheng SH; Genzyme, a Sanofi Company, Framingham, MA 01701, USA.
  • Davies JC; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Department of Gene Therapy, Imperial College, London, UK.
  • Davies LA; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Gene Medicine Research Group, NDCLS, John Radcliffe Hospital, Oxford University, Oxford, UK.
  • Dayan A; Toxicology Consult, London, UK.
  • Gill DR; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Gene Medicine Research Group, NDCLS, John Radcliffe Hospital, Oxford University, Oxford, UK.
  • Griesenbach U; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Department of Gene Therapy, Imperial College, London, UK.
  • Higgins T; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Department of Gene Therapy, Imperial College, London, UK.
  • Hyde SC; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Gene Medicine Research Group, NDCLS, John Radcliffe Hospital, Oxford University, Oxford, UK.
  • Innes JA; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Scottish Adult Cystic Fibrosis Service, Western General Hospital, Edinburgh, UK.
  • McLachlan G; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Roslin Institute, University of Edinburgh, Edinburgh, UK.
  • Porteous D; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Medical Genetics Section, Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • Pringle I; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Gene Medicine Research Group, NDCLS, John Radcliffe Hospital, Oxford University, Oxford, UK.
  • Scheule RK; Genzyme, a Sanofi Company, Framingham, MA 01701, USA.
  • Sumner-Jones S; 1] UK CF Gene Therapy Consortium, London, Oxford and Edinburgh, UK [2] Gene Medicine Research Group, NDCLS, John Radcliffe Hospital, Oxford University, Oxford, UK.
Gene Ther ; 21(1): 89-95, 2014 Jan.
Article in En | MEDLINE | ID: mdl-24196086
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasmids / Genetic Therapy / Cystic Fibrosis Transmembrane Conductance Regulator / Genetic Vectors / Lipids / Lung Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: Gene Ther Journal subject: GENETICA MEDICA / TERAPEUTICA Year: 2014 Document type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasmids / Genetic Therapy / Cystic Fibrosis Transmembrane Conductance Regulator / Genetic Vectors / Lipids / Lung Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: Gene Ther Journal subject: GENETICA MEDICA / TERAPEUTICA Year: 2014 Document type: Article Affiliation country: United kingdom